Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingyi Jiangzhi Decoction (QYD) is a traditional Chinese medicine (TCM) formula composed of eight herbs: Rheum officinale (da-huang), Bupleurum chinense (chai-hu), Scutellaria baicalensis Georgi (huang-qin), Paeonia lactiflora Pall. (bai-shao), Aucklandia costus Falc. (mu-xiang), Corydalis yanhusuo (yan-hu-suo), Gardenia jasminoides J. Ellis (zhi-zi), and Natrii Sulfas (mang-xiao)[2][4]. It is primarily used in the treatment of acute pancreatitis and related inflammatory conditions[3][5]. The decoction exerts anti-inflammatory, antioxidant, immune regulatory effects, promotes intestinal barrier recovery, and induces apoptosis in target cells[2][4]. Mechanistically, QYD acts by inhibiting NLRP3 inflammasome activation in macrophages and regulating the MyD88/NF-κB/NLRP3/caspase-1 signaling pathway to reduce systemic inflammation during acute pancreatitis[2][3][5]. Its multi-component nature allows for multitargeted intervention across several biological pathways relevant to inflammation and organ protection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qingyi Jiangzhi Decoction.